---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-26-000006"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:26:18.381515+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma private placement $20.2M; Phase 1 IV rademikibart shows rapid bronchodilation; Phase 3 AD efficacy

## Summary
- Raised $20.2M via private placement of 6.13M shares at $3.25; led by Panacea Venture; extends cash runway into H2 2027.
- Phase 1 IV rademikibart: rapid FEV1 improvements of 200-400 mL within 15 mins in asthma/COPD, maintained through Day 29.
- Phase 3 AD study: 96.6% EASI-75, 87.1% IGA 0/1, 85.3% EASI-90 at week 52; safety comparable to placebo, low conjunctivitis.
- Phase 2 Seabreeze STAT data for acute exacerbations expected mid-2026; plans to meet FDA for Phase 3 alignment.

## SEC filing metadata
- accession: 0001835268-26-000006
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/0001835268-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/cntb-20260329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-26-000006
- JSON: https://secwatch.observer/filing/0001835268-26-000006.json
- Plain text: https://secwatch.observer/filing/0001835268-26-000006.txt

## Key facts
- Material Agreements
  Connect Biopharma Holdings Ltd entered into Purchase Agreement with the purchasers named therein valued at approximately $20.2 million (effective 2026-03-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers named therein
  - Value: approximately $20.2 million
  - Effective: 2026-03-29
  source text: On March 29, 2026, Connect Biopharma Holdings Limited (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 6,130,000 shares (the “Shares”) of the Company’s ordinary shares, par value $0.000174 per share (the “Ordinary Shares”), at a price of $3.25 per Share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/0001835268-26-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.